GeneDx has initiated a patient access program in association with leading biopharma companies, aiming to enhance access to exome sequencing for pediatric epilepsy patients.
To be eligible for the test, patients must meet certain requirements, which include a test ordered by an authorized healthcare provider, as well as being a US citizen of 18 years or below who has experienced an unprovoked seizure under 8 years of age and have no confirmed diagnosis of a neurodevelopmental disorder.
The company asserts that expanded access to exome testing will result in more children receiving a diagnosis and provide better understanding of the relationship between genes and diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.